The development of bispecific antibodies and their applications in tumor immune escape
Open Access
- 2 May 2017
- journal article
- review article
- Published by Springer Science and Business Media LLC in Experimental Hematology & Oncology
- Vol. 6 (1), 1-6
- https://doi.org/10.1186/s40164-017-0072-7
Abstract
During the past two decades, a great evolution of bispecific antibodies (BsAbs) for therapeutic applications has been made. BsAbs can bind simultaneously two different antigens or epitopes, which leads to a wide range of applications including redirecting T cells or NK cells to tumor cells, blocking two different signaling pathways, dual targeting of different disease mediators, and delivering payloads to targeted sites. Aside from approved catumaxomab (anti-CD3 and anti-EpCAM) and blinatumomab (anti-CD3 and anti-CD19), many more BsAbs are now in various phases of clinical development. Here, this review focus on the development of bispecific antibodies and their applications in tumor immune escape.Keywords
Funding Information
- National Natural Science Foundation of China (30971291)
- National Natural Science Foundation of China (81400176, 81572993)
- CAMS Initiative for Innovative Medicine (2016-I2M-1-007, 2016-I2M-3-013)
This publication has 48 references indexed in Scilit:
- Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicitymAbs, 2013
- Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trialJournal of Translational Medicine, 2013
- Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchangeProceedings of the National Academy of Sciences of the United States of America, 2013
- Anti‐CD3 × anti‐GD2 bispecific antibody redirects T‐cell cytolytic activity to neuroblastoma targetsPediatric Blood & Cancer, 2012
- Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3Molecular Cancer Therapeutics, 2012
- World Bispecific Antibody Summit, September 27–28, 2011, Boston, MAmAbs, 2012
- Strategies for extended serum half-life of protein therapeuticsCurrent Opinion in Biotechnology, 2011
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid PhagocytosisCell, 2009
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem CellsCell, 2009
- The discovery of receptor tyrosine kinases: targets for cancer therapyNature Reviews Cancer, 2004